USPTO Examiner SOROUSH ALI - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17123866NEW CANNABIS TABLET FORMULATIONS AND COMPOSITIONS AND METHODS OF MAKING THE SAMEDecember 2020June 2022Abandon1830YesNo
17123307System and Method for Antibiotic Delivery Using Single-Walled Carbon NanotubesDecember 2020June 2024Abandon4230NoNo
17122072VASOPROTECTIVE AND CARDIOPROTECTIVE ANTIDIABETIC THERAPYDecember 2020October 2023Allow3411NoNo
17252532HYDROGEL COMPOSITION COMPRISING A CROSSLINKED POLYMERDecember 2020May 2024Allow4111NoNo
17120507ANTIMICROBIAL COLLOIDAL SILVER PRODUCTS AND METHOD OF MAKING SAMEDecember 2020October 2023Abandon3410NoNo
17111873PROCESS FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONSDecember 2020May 2022Abandon1821NoNo
17101536AVOIDING GAG REFLEX TO ENABLE SWALLOWING PILLSNovember 2020September 2021Allow1000NoNo
17057103PATCH FOR ALLEVIATION AND PREVENTION OF ACNENovember 2020March 2023Allow2730YesNo
16952209METHODS AND POLYMER COMPOSITIONS FOR TREATING RETINAL DETACHMENT AND OTHER OCULAR DISORDERSNovember 2020January 2023Abandon2640NoNo
16952211METHODS AND POLYMER COMPOSITIONS FOR TREATING RETINAL DETACHMENT AND OTHER OCULAR DISORDERSNovember 2020January 2021Allow200YesNo
16952214METHODS AND POLYMER COMPOSITIONS FOR TREATING RETINAL DETACHMENT AND OTHER OCULAR DISORDERSNovember 2020January 2021Allow200YesNo
17050135TOPICAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ANAL FISSURES AND HEMORRHOIDSOctober 2020April 2023Allow2920NoNo
17063491BISMUTH-THIOLS AS ANTISEPTICS FOR EPITHELIAL TISSUES, ACUTE AND CHRONIC WOUNDS, BACTERIAL BIOFILMS AND OTHER INDICATIONSOctober 2020September 2022Allow2410NoNo
17060551BIOIDENTICAL PROGESTERONE CREAM INFUSED WITH NANOEMULSIFIED CBDOctober 2020September 2023Abandon3511NoNo
17028319TOPICAL THERAPY FOR THE TREATMENT OF SKIN MALIGNANCIES USING NANOPARTICLES OF TAXANESSeptember 2020September 2021Allow1200YesNo
17024268WET-PACKED SOFT HYDROGEL OCULAR INSERTSSeptember 2020September 2023Allow3630NoYes
17018865OPHTHALMIC FORMULATIONS OF CETIRIZINE AND METHODS OF USESeptember 2020July 2022Allow2320NoNo
16980377TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTSSeptember 2020November 2023Abandon3811NoNo
17002399POWDER FOR ACHIEVING HEMOSTASISAugust 2020March 2023Allow3010NoNo
16988077MORINGA OLEIFERA NANOPARTICLESAugust 2020May 2021Allow900YesNo
16986627ANTIBACTERIAL AND DEODORIZING LEATHERAugust 2020September 2022Allow2520NoNo
16967672Compositions and Methods for the Removal of Extraneous Calcium HydroxyapatiteAugust 2020January 2022Abandon1710NoNo
16965335Compositions For Treating And/Or Preventing Photodynamic Therapy Side EffectsJuly 2020April 2023Abandon3330YesNo
16965353Therapeutic Compositions for Enhanced Healing of Wounds and ScarsJuly 2020July 2023Allow3530YesNo
16962948COMPOSITIONS FOR THE TREATMENT OF A DISEASE OF THE URINARY TRACT AND TREATMENT OF A DISEASE INVOLVING THE INTRACELLULAR DELIVERY OF THE PARTICLE OR A MEDICAMENT CONTAINED THEREINJuly 2020November 2023Abandon4021NoNo
16961017PALONOSETRON FOR THE TREATMENT OR PREVENTION OF NAUSEA AND VOMITINGJuly 2020June 2022Allow2420NoNo
16923207ANTIMICROBIAL FABRIC TREATMENTJuly 2020December 2021Abandon1720NoNo
16921628PHARMACEUTICAL FORMULATIONJuly 2020February 2022Allow1910NoNo
16960077TREATMENT OF MYOPIC PROGRESSIONJuly 2020August 2022Allow2520NoNo
16914230ENHANCING AAV-MEDIATED TRANSDUCTION OF OCULAR TISSUES WITH HYALURONIC ACIDJune 2020June 2021Allow1120YesNo
16899699Methods and Compositions For Improving Outcomes of Cancer PatientsJune 2020June 2023Abandon3621NoYes
16897758STORAGE-STABLE SOLID PEROXYMONOSULFATE COMPOSITIONJune 2020September 2021Allow1520YesNo
16897308METHODS AND COMPOSITIONS FOR THE TREATMENT OF ACNEJune 2020August 2022Abandon2740NoNo
16892157ORALLY ADMINISTRABLE COMPOSITIONS COMPRISING CALCIUMJune 2020April 2023Abandon3410NoNo
1687881624-karat Edible Gold Glitter LipscrubMay 2020March 2022Abandon2210NoNo
16866160WOUND DEBRIDEMENT COMPOSITION AND METHOD FOR TREATING WOUNDSMay 2020June 2022Abandon2520YesNo
16849057COMPOSITION FOR AMELIORATING POST-CEREBRAL STROKE SEQUELAApril 2020May 2024Abandon4960NoNo
16841937TREATMENT OF MIGRAINEApril 2020July 2022Allow2740YesYes
16838870METHOD FOR EXTENDING TIME OF ACTIVITY OF CHLORITE-BASED BIOCIDESApril 2020October 2022Allow3150NoNo
16835921PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITORMarch 2020December 2021Allow2011NoNo
16646891METHODS OF PREPARING COMPOSITIONS CONTAINING THYMOQUINONEMarch 2020March 2022Allow2401YesNo
16806703VETERINARY CANNABINOID, MENTHOL AND ANESTHETIC COMPOSITIONS AND METHODSMarch 2020January 2022Allow2310NoNo
16806333CANNABINOID AND ANESTHETIC COMPOSITIONS AND METHODSMarch 2020December 2020Allow1020YesNo
16805707All N 1 Summer ProtectionFebruary 2020February 2022Abandon2320NoNo
16643418KELOID PREVENTION OR TREATMENT METHOD USING LIQUID PHASE PLASMAFebruary 2020September 2021Allow1920NoNo
16802181HIGH-PRECISION DRUG DELIVERY BY DUAL-DOMAIN OCULAR DEVICEFebruary 2020July 2021Allow1610NoNo
16873181AST-120 for non-systemic newborn and pediatric hyperammonemia therapyFebruary 2020April 2024Abandon5070YesNo
16787673PREVENTING OR REDUCING PLANT GROWTH BY BIOCEMENTATIONFebruary 2020July 2022Allow2950YesNo
16637182WATER VAPOR SUPPRESSION MATERIAL AND PRODUCTION METHOD THEREFORFebruary 2020October 2024Abandon5621NoNo
16635481Multi-Mineral Supplement for Improved Bone DensityJanuary 2020June 2022Abandon2910NoNo
16748345ANTIMICROBIAL COLLOIDAL SILVER PRODUCTS AND METHOD OF MAKING SAMEJanuary 2020June 2021Abandon1610NoNo
16631377METHODS OF CONTROLLING OR PREVENTING INFESTATION OF SOYBEAN PLANTS BY PHYTOPATHOGENIC MICROORGANISMSJanuary 2020June 2021Allow1720NoNo
16740007Trans-mucosal Delivery System for TestosteroneJanuary 2020April 2023Allow3950YesNo
16629897FIBRILLAR-PROTEIN BASED COMPOSITIONS AND USES THEREOFJanuary 2020October 2023Abandon4540NoNo
16628476PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATIONJanuary 2020December 2022Allow3630YesNo
16733072ORIENTED P4HB IMPLANTS CONTAINING ANTIMICROBIAL AGENTSJanuary 2020November 2020Allow1010YesNo
16725667Modified Biological Control Agents and Their UsesDecember 2019August 2022Allow3110NoNo
16626194METHOD FOR TREATING FIBRILLAR COLLAGENOUS CONDITIONSDecember 2019November 2021Allow2320YesNo
16722167COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF OBESITYDecember 2019April 2020Allow400YesNo
16620674HIGH GLYCEROL COMPOSITION COMPRISING BLENDS OF ALKYL ISETHIONATE AND ALKYL TAURATEDecember 2019February 2024Abandon5140NoYes
16706142TOPICAL THERAPY FOR THE TREATMENT OF SKIN MALIGNANCIES USING NANOPARTICLES OF TAXANESDecember 2019August 2020Allow910NoNo
16699307PREVENTION OF BOAR TAINT AND AGGRESSIONNovember 2019December 2021Abandon2530NoNo
16618167RESORBABLE BIODEGRADABLE MEDICAL AND COSMETIC COMPOSITION COMPRISING POLY(1,3-TRIMETHYLENE CARBONATE)November 2019January 2022Allow2610YesNo
16618013CONTROLLABLE ION RELEASE CALCIUM PARTICLES, METHOD FOR PRODUCING SAME AND USE THEREOFNovember 2019August 2022Allow3211NoNo
16693422Photosensitive Dyes and Method of Using Said DyesNovember 2019March 2022Abandon2720YesNo
16695001HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINENovember 2019September 2020Allow1010NoNo
16690558OXYGEN-GENERATING COMPOSITIONS FOR ENHANCING CELL AND TISSUE SURVIVAL IN VIVONovember 2019January 2022Allow2640NoNo
16615148COMPOSITION FOR PREVENTING OR TREATING VISCERAL FAT OBESITY CONTAINING EXTRACT OF SALVIA MILTIORRHIZA RADIXNovember 2019July 2021Abandon2010NoNo
16688797ALCOHOL-RESISTANT DRUG FORMULATIONSNovember 2019January 2022Allow2630YesNo
16686799BUCKWHEAT HONEY AND BACITRACIN WOUND-HEALING DRESSINGNovember 2019September 2021Allow2220NoNo
16687337HAIR TREATMENTSNovember 2019October 2021Allow2320NoNo
16613858USE OF NATURALLY GLYCOSYLATED POLYPHENOLS AS PROTECTIVE AGENTS AGAINST THE EFFECTS OF ULTRAVIOLET IRRADIATIONNovember 2019July 2022Allow3230NoNo
16612868DEAD SEA SALTS COSMETIC COMPOSITIONSNovember 2019July 2022Abandon3240NoNo
16612128AROMATIC CULTURE PRODUCT OF MICROORGANISMNovember 2019October 2021Allow2420YesNo
16608907YARROW FRESH-PLANT PRESSED JUICE CONCENTRATE, PRODUCTION, AND USEOctober 2019September 2021Allow2320YesNo
16664698METHODS OF TREATMENT WITH MIXED METAL COMPOUNDOctober 2019July 2024Abandon5741NoYes
16664227WOUND HEALING COMPOSITIONS AND METHODS OF USEOctober 2019February 2020Allow400NoNo
16659186MODIFIED BIOLOGICAL CONTROL AGENTS AND THEIR USESOctober 2019July 2021Abandon2101NoNo
16493242METHODS OF TREATMENT OF HLA-B27 RELATED INFLAMMATORY DISEASES AND COMPOSITIONS RELATED TO SAMESeptember 2019July 2022Abandon3420NoNo
16491374AEROSOL DEVICE FOR HAIR SHAPING AND/OR HAIRSTYLE HOLDSeptember 2019March 2022Allow3130YesNo
16490657COMPOSITIONS AND METHODS FOR PROMOTING HEMOSTASISSeptember 2019April 2021Abandon2020NoNo
16555241VETERINARY CANNABINOID, MENTHOL AND ANESTHETIC COMPOSITIONS AND METHODSAugust 2019December 2020Allow1520YesNo
16488938COMPOSITION FOR DERMAL INJECTIONAugust 2019May 2021Allow2100YesNo
16488848COSMETIC COMPOSITION FOR WRINKLE REDUCTION OR ANTI-INFLAMMATION, CONTAINING SUBSTANCE PAugust 2019March 2023Abandon4340NoNo
16484870DRUG DELIVERY FORMULATION FOR TREATING MENTAL ILLNESS OR CENTRAL NERVOUS SYSTEM DISORDERAugust 2019February 2022Allow3021NoNo
16536557Activation And Stabilization Of Basic Aluminum Chloride Solution By ZincAugust 2019January 2023Abandon4120NoYes
16532699METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENTAugust 2019December 2020Abandon1610NoNo
16526874CAT AND DOG STERILIZATION BY ESTROGENIC COMPOUNDSJuly 2019June 2021Allow2340YesNo
16525569HYALURONIC ACID BASED FORMULATIONSJuly 2019March 2023Abandon4460YesNo
16521547HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINEJuly 2019July 2021Allow2430NoNo
16516167COMPOSITION AND METHOD FOR THE ALLEVIATION OF EFFECTS OF ALCOHOL CONSUMPTIONJuly 2019December 2020Abandon1710NoNo
16460308METHOD OF TREATING A SKIN CONDITIONJuly 2019February 2022Allow3230NoNo
16475397INSECT PEST CONTROL PRODUCT AND INSECT PEST CONTROL METHODJuly 2019May 2021Abandon2320YesNo
16473927INSECT REPELLENT PRODUCTJune 2019May 2021Abandon2330NoNo
16451967ENCAPSULATION OF METAL OXIDE NANOMATERIALS FOR CONTROLLED RELEASE AND TARGETED DELIVERYJune 2019June 2024Abandon6061YesNo
16449431METHOD AND FORMULATION FOR TREATMENT OF WOUNDS BY NEW TISSUE REGENERATION WITH REDUCED TRAUMA AND SCAR TISSUE FORMATIONJune 2019November 2023Abandon5370YesNo
16471747OIL-IN-WATER EMULSION AND COSMETIC USE THEREOFJune 2019August 2022Allow3840YesNo
16440557USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASESJune 2019September 2021Abandon2720NoYes
16433660BISMUTH-THIOLS AS ANTISEPTICS FOR AGRICULTURAL, INDUSTRIAL AND OTHER USESJune 2019February 2021Abandon2010NoNo
16422467ORAL COMPOSITION AND METHODMay 2019November 2022Allow4240YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SOROUSH, ALI.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
19
Examiner Affirmed
15
(78.9%)
Examiner Reversed
4
(21.1%)
Reversal Percentile
34.8%
Lower than average

What This Means

With a 21.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
99
Allowed After Appeal Filing
25
(25.3%)
Not Allowed After Appeal Filing
74
(74.7%)
Filing Benefit Percentile
37.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SOROUSH, ALI - Prosecution Strategy Guide

Executive Summary

Examiner SOROUSH, ALI works in Art Unit 1617 and has examined 613 patent applications in our dataset. With an allowance rate of 45.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner SOROUSH, ALI's allowance rate of 45.2% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SOROUSH, ALI receive 2.76 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SOROUSH, ALI is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +37.9% benefit to allowance rate for applications examined by SOROUSH, ALI. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.4% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 22.4% of cases where such amendments are filed. This entry rate is in the 31% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 88.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 67.2% of appeals filed. This is in the 53% percentile among all examiners. Of these withdrawals, 61.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 43.2% are granted (fully or in part). This grant rate is in the 34% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 59% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.